Dual-targeted therapy with patuximab and trastuzumab can provide significant benefit to patients with human epidermal growth factor receptor-2 (HER-2)-positive breast cancer. With the advent of the dual-targeted era, any patient eligible for mono-targeted therapy can be considered for dual-targeted therapy. The dual-targeted therapy of trastuzumab plus patuximab in combination with chemotherapy regimens is superior to single-targeted drug therapy, especially for patients with lymph node-positive or hormone receptor-negative breast cancer who are at high risk of recurrence. The use of anti-HER-2 dual-targeted therapy for HER-2-positive breast cancer can achieve a higher rate of complete pathological remission and better prognosis in neoadjuvant therapy, and similarly better survival benefit in adjuvant therapy and late-stage salvage therapy. The application of targeted drugs has revolutionized the treatment options and outcomes for HER-2-positive breast cancer patients. Modern breast cancer treatment is individualized and precise under the guidance of molecular typing, which requires clinicians to adopt different therapeutic options for patients with HER-2 positive breast cancer at different stages of the disease and at different economic levels.